In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory Flexibility For Rare Diseases: How Do You Routinize Elasticity?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA tries to MaPP out how and when reviewers can be flexible, moving from 'one-off' to 'boutique' evaluation.

You may also be interested in...



FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Frank Sasinowski updates his 2012 landmark analysis and finds that FDA maintained its rate of flexibility in the evidentiary standards for approval of orphan products.

Biomarkers In Orphan Studies Still Need Past Experience, FDA Says

Rare Disease groups work to finalize white paper on accelerated approval, but FDA questions whether a rules-based biomarker qualification process is possible.

Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?

FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.

Related Content

Topics

UsernamePublicRestriction

Register

PS079564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel